OncoMatch/Clinical Trials/NCT07698899
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
Is NCT07698899 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies 25 mCi 177Lu- DTPA-omburtamab for recurrent medulloblastoma.
Treatment: 25 mCi 177Lu- DTPA-omburtamab — The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Radioligand therapy
Cancer type
Glioblastoma
Biomarker criteria
Required: CD276 expression (testing required; no eligibility threshold specified)
Demographics
Lab requirements
Blood counts
ANC ≥ 0.5 x 10^9/L (no G-CSF within 7 days or pegfilgrastim within 14 days prior to enrollment); Platelet count ≥ 75 x 10^9/L (≥ 50 x 10^9/L if known bone marrow infiltration, no platelet transfusion within 7 days prior to enrollment)
Kidney function
Serum creatinine must be below age/gender-specific thresholds (see table in protocol, derived from Schwartz formula)
Liver function
Bilirubin ≤ 1.5 x ULN for age (or ≤ 3 x ULN if Gilbert's syndrome); SGPT (ALT) < 135 U/L (ULN for SGPT is 45 U/L)
Cardiac function
Cardiac toxicity should be < grade 2
Peripheral absolute neutrophil count (ANC) ≥ 0.5x 10^9/L... Platelet count ≥ 75 x 10^9/L... Adequate Renal Function... Adequate Liver Function... Cardiac, pulmonary, and gastrointestinal system toxicity should all be < grade 2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07698899 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CD276?
Yes, CD276 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 22 years or younger and at least 3 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages